Support our Foundation of Myology project
ARGX113-2308 ADAPT (Seroneg)
A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous efgartigimod in adult patients with seronegative generalised myasthenia gravis.